26
|
Pothuri B, Sawaged Z, Lee J, Musa F, Lutz K, Reese E, Blank S, Boyd L, Curtin J, Li X, Goldberg J, Muggia F. A phase II feasibility study of nab-paclitaxel and carboplatin in chemotherapy naïve epithelial neoplasms of the uterus. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.571] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Brodsky A, Lee J, Asgari S, Fehniger J, Levine D, Pothuri B. Genetic counselor involvement with abnormal immunohistochemistry results improves genetic testing in patients with endometrial cancer. Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Gonzalez A, Mirza M, Vergote I, Li Y, Hazard S, Clark R, Graybill W, Pothuri B, Monk B. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: Blinded pooled interim safety data from the PRIMA Study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy285.150] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Lee J, Brodsky A, Madden N, Musselman K, Huang K, Jain S, Gerber D, Fehniger J, Pothuri B. The post-anesthesia care unit experience to enable successful and safe same-day discharge following robotic hysterectomies. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
30
|
Sandler G, Lee J, Jiang E, Gerber D, Fehniger J, Musselman K, Madden N, Boyd L, Pothuri B. Mini-laparotomy for large specimen retrieval in robotic gynecologic surgery: Key to a successful minimally invasive procedure. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
31
|
Gerber D, Khouri O, Smith M, Lee J, Grifo J, Pothuri B, Boyd L. An opportunity lost: Low rates of fertility counseling in pathogenic BRCA mutation carriers. Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
32
|
Gerber D, Olsen A, Lee J, Fehniger J, Asgari S, Cantor A, Martineau J, Ginsburg O, Smith J, Levine D, Pothuri B. Risk-reducing surgery for BRCA mutations: Are we adhering to the guidelines? Gynecol Oncol 2018. [DOI: 10.1016/j.ygyno.2018.04.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Gonzalez Martin A, Rojas L, Braly P, Barter J, O'Malley D, Oza A, Haggerty A, Vulsteke C, Provencher D, Graybill W, Li Y, Malinowska I, Mirza M, Vergote I, Pothuri B, Monk B. A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Madden N, Frey M, Lee J, Musselman K, Chern J, Joo L, Blank S, Pothuri B. Safety of robotic-assisted gynecologic surgery and early hospital discharge in elderly patients. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
35
|
Foley C, Lee J, Timor Tritsch I, Blank S, Pothuri B, Curtin J, Boyd L. Reoperation and recurrence rates in women undergoing conservative surgery for low malignant potential tumors. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Kim S, Frey M, Madden N, Musselman K, Chern J, Lee J, Boyd L, Blank S, Pothuri B, Curtin J. How old is too old: Safety of minimally invasive gynecologic surgery and early hospital discharge in the oldest elderly. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
37
|
Comfort A, Frey M, Musselman K, Chern J, Lee J, Joo L, Radford M, Ford S, Blank S, Boyd L, Curtin J, Pothuri B. Predictors of port site hernia necessitating operative intervention in patients undergoing robotic surgery. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
38
|
Musselman K, Frey M, Sapra K, Madden N, Lee J, Chern J, Blank S, Pothuri B. Indication for robotic-assisted surgery influences perioperative outcomes and hospital readmissions among women undergoing gynecologic procedures. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
39
|
David-West G, Musa F, Frey M, Boyd L, Pothuri B, Curtin J, Blank S. Cross-sectional study on the impact of a natural disaster on delivery of gynecologic oncology care. Gynecol Oncol 2014. [DOI: 10.1016/j.ygyno.2014.03.394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
40
|
Musa F, Alard A, Blank S, Pothuri B, Curtin J, Schneider R. mTOR complex inhibition as a novel therapeutic strategy in high-grade papillary serous ovarian cancer. Gynecol Oncol 2014. [DOI: 10.1016/j.ygyno.2014.03.314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
41
|
Pothuri B. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. Ann Oncol 2014; 24 Suppl 8:viii22-viii27. [PMID: 24131965 DOI: 10.1093/annonc/mdt307] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Ovarian cancer is the deadliest among gynecologic cancers. Hereditary cancer related to BRCA1/2 gene mutations account for ~10%-12% of ovarian cancers. The BRCA1/2 proteins are important in homologous recombination (HR) repair of DNA. Patients with BRCA1/2 mutations have been reported to have improved chemosensitivity to platinum agents, longer disease-free intervals, and longer survivals than nonhereditary counterparts. Recent interest in poly(ADP-ribosyl) polymerase (PARP) proteins which are key components of base excision repair, has led to the development of PARP inhibitors; tumors arising in BRCA1/2 mutation carriers and/or with HR deficiency (HRD) are particularly sensitive to the action of these drugs. As 60%-80% of all advanced ovarian cancers are high-grade serous type, exhibiting HRD in at least 50% (referred as BRCAness) future antitumor strategies may depend on identifying these defects through molecular testing. Once HRD becomes amenable to routine testing, a larger group of ovarian cancer patients than are currently considered for PARP inhibitor trials, may benefit from such targeted therapy.
Collapse
|
42
|
Ling H, Muggia F, Speyer J, Curtin J, Blank S, Boyd L, Pothuri B, Li X, Goldberg J, Tiersten A. Combination of irinotecan and bevacizumab for heavily pretreated recur- rent ovarian cancer: A phase II trial. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
43
|
Blank S, Greenwald J, Boyd L, Pothuri B, Curtin J. Trial design and endpoint definition for conservative management of endometrial neoplasia. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
44
|
Verschraegen CF, Czok S, Muller CY, Boyd L, Lee SJ, Rutledge T, Blank S, Pothuri B, Eberhardt S, Muggia F. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer. Ann Oncol 2012; 23:3104-3110. [PMID: 22851407 DOI: 10.1093/annonc/mds172] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Suppression of neoangiogenesis and pegylated liposomal doxorubicin (PLD) each contribute to the management of platinum-resistant/refractory ovarian cancer. The aim of this study is to test the combination of bevacizumab and PLD in women with resistant or refractory ovarian cancer. METHODS Eligibility criteria were no more than two prior treatments with platinum-containing regimens and one additional regimen, without anthracyclines. Treatment was administered every 3 weeks (bevacizumab 15 mg/kg beginning on cycle 2 and PLD 30 mg/m(2)). The primary end point was progression-free survival (PFS) at 6 months; the secondary end points included side-effects, overall response rates (ORR) and survival (OS). RESULTS Forty-six patients were enrolled. The average number of courses administered was 7. The median PFS was 6.6 months (range 1-24.6 months) according to Gynecologic Cancer Intergroup Committee (GCIC) criteria and 7.8 months (range 2-13.3 months) according to Response Evaluation Criteria in Solid Tumors (RECIST). The median OS was 33.2 months (range 3-37.5+ months). The ORR was 30.2% [95% confidence interval (CI) 17.2-46.1] and the clinical benefit rate (CBR) was 86.1% (95% CI 72.1-94.7). Adverse events included mucosal and dermal erosions (30% grade 3) and asymptomatic cardiac dysfunction. Additional toxic effects included hypertension, headache, renal dysfunction and proteinuria, wound healing delay, and one episode each of central nervous system (CNS) ischemia and hemolytic uremic syndrome. CONCLUSION PLD with bevacizumab has improved activity in recurrent ovarian cancer with increased toxicity.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors/adverse effects
- Angiogenesis Inhibitors/therapeutic use
- Antibiotics, Antineoplastic/adverse effects
- Antibiotics, Antineoplastic/therapeutic use
- Antibodies, Monoclonal, Humanized/adverse effects
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Bevacizumab
- Bridged-Ring Compounds/pharmacology
- Carcinoma, Ovarian Epithelial
- Disease-Free Survival
- Doxorubicin/adverse effects
- Doxorubicin/therapeutic use
- Drug Resistance, Neoplasm
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local/drug therapy
- Neoplasms, Glandular and Epithelial/drug therapy
- Neoplasms, Glandular and Epithelial/mortality
- Ovarian Neoplasms/drug therapy
- Ovarian Neoplasms/mortality
- Platinum/pharmacology
- Taxoids/pharmacology
- Treatment Outcome
Collapse
|
45
|
Pothuri B, Sparano J, Blank S, Curtin J, Chuang E, Hershman D, Tiersten A, Liebes L, Chen A, Muggia F. Phase I study of the PARP inhibitor ABT-888 (veliparib) and pegylated liposomal doxorubicin (PLD) in recurrent ovarian (ov) and breast (br) cancers. Gynecol Oncol 2012. [DOI: 10.1016/j.ygyno.2011.12.053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
46
|
Zechmeister J, Pua T, Novetsky A, Ferrante K, Pothuri B. A Prospective Comparison of Post-Operative Pain in Robotic Versus Laparoscopic Gynecologic Surgery. J Minim Invasive Gynecol 2011. [DOI: 10.1016/j.jmig.2011.08.371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Pua T, Jewell A, Novetsky A, Lee J, Friedman K, Whyte J, Boyd L, Pothuri B, Curtin J, Blank S. Incidental gynecologic FDG-PET/CT findings in women with a history of breast cancer. Gynecol Oncol 2011. [DOI: 10.1016/j.ygyno.2010.12.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Boyd LR, Novetsky A, Pua TL, Pothuri B, Curtin JP, Wallach RC, Blank SV. Intraperitoneal chemotherapy: Who, what, when, and how in diverse academic settings. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Muggia FM, Boyd L, Liebes L, Downey A, Muller C, Pothuri B, Blank S, Rutledge T, Fishman D, Verschraegen C. Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5548] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5548 Background: PLD activity in platinum-resistant OC is modest. B, with its activity in platinum(Plat)-sensitive and Plat-resistant patients (pts), has not been combined with PLD. PLD intratumoral concentrations, if affected by B, might be reflected in PLD PK. This phase II study of PLD + B was started in 2007 to accrue 48 pts, unless 4 serious (> grade 3) adverse events (AEs) supervened. Methods: Improvement in progression-free survival (PFS) at 6 m from 25 to 40% at 6 m in Plat-resistant OC is primary endpoint. PK of PLD alone at 1h, d 7 and d 21 (cycle 1) vs with B (cycle 2), safety, and response rates (RECIST and CA125 criteria) were secondary endpoints. Dosing: PLD 30 mg/m2 followed by B 15 mg/kg on cycles 2–7 (with option to continue) d 1 every 3 w. Pts recurring within 6 m of platinum-based treatment for OC after < 3 prior regimens (but no PLD or B) were eligible. Exclusions: bowel obstruction, prior perforation, uncontrolled hypertension, or vascular disease. Hematologic, mucocutaneous and renal toxicities were evaluated prior to each cycle, MUGA scans every third cycle; disease status by CA125 and/or RECIST every third cycle. Results: 21 of 24 pts enrolled to date are evaluable. Median age is 65, range 52–83; most had 2 prior chemotherapy regimens. Median 6 (range 3–12) cycles were given with 6 off study with progression at 3–7 cycles. RECIST and CA125 responses are under review; in 11 pts with baseline CA125 of > 40 IU/mL, median increase was 31% by cycle 2; later falling to -57%. AEs did not exceed grade 3; hand-foot syndrome led to PLD dose reduction in 8 pts (33%); asymptomatic decreases in left ventricular ejection fraction (LVEF) >10% in 3 pts were noted, with treatment discontinuation in 1. The mean (±SEM) secondary PK parameter estimates for Cmax, AUC, and elimination half life were 4.5 ± 0.5 ug/mL, 651.7 ± 61 ug/mL x h, and 93.3 ± 19.7 h, respectively. Conclusions: Cycles 1 and 2 PLD PK do not differ. PLD + B is tolerable with PLD dose modifications. Declines in LVEF in 1 institution have uncertain causality. Midway into the trial, safety and time on study encourage completion for study primary endpoint. [Table: see text]
Collapse
|
50
|
Gogoi R, Brusati A, Liu M, Curtin JP, Blank SV, Pothuri B. Thromboembolism and outcomes in patients with gynecologic malignancies. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|